Globus Medical to buy neurostim developer Nevro for $250M
With Globus paying $5.85 for each of Nevro’s outstanding shares, that amounts to a 27% premium over a 90-day weighted average.
With Globus paying $5.85 for each of Nevro’s outstanding shares, that amounts to a 27% premium over a 90-day weighted average.
